An Open Clinical Study to Explore the Safety, Tolerance and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Umbilical cord mesenchymal stem cell injection Shanghai Life Science And Technology (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Shanghai Life Science and Technology
Most Recent Events
- 24 Apr 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 24 Oct 2022 Planned initiation date changed from 1 Aug 2022 to 1 Oct 2022.
- 24 Oct 2022 Status changed from not yet recruiting to recruiting.